By admin 
In a significant stride toward understanding and potentially treating these devastating conditions, researchers at Sanford Burnham Prebys reported on July 17, 2026, in the prestigious journal Science Advances that another protein, Sorting-Related Receptor with A-type Repeats (SORLA), may possess an inherent protective capacity against this tau-induced damage. Their groundbreaking findings illuminate a previously underappreciated mechanism of neuroprotection and raise the tantalizing possibility that future therapeutic strategies could be designed to strengthen this natural defense, thereby reducing the harmful effects of tau-related diseases and offering new hope to millions affected worldwide.
The urgent need for effective treatments for Alzheimer’s disease and related dementias cannot be overstated. With an aging global population, the prevalence of these conditions is projected to rise dramatically, placing immense strain on healthcare systems and individual families. While much attention has historically been paid to amyloid-beta plaques, the other pathological hallmark of Alzheimer’s, the role of tau tangles has gained increasing prominence. These intracellular aggregates are strongly correlated with cognitive decline, synaptic loss, and neuronal death, making them a prime target for therapeutic intervention.
Tau is normally found throughout the brain and nervous system, particularly abundant in axons, where it plays a vital role in maintaining the structure and stability of microtubules. These dynamic structures are essential for axonal transport, the process by which nutrients, organelles, and signaling molecules are moved along the neuron, crucial for communication and overall neuronal health. In Alzheimer’s disease and other tauopathies, however, this delicate balance is disrupted. Tau proteins become hyperphosphorylated—meaning an excessive number of phosphate groups attach to the protein—leading to its detachment from microtubules. Once detached, these abnormally phosphorylated tau proteins begin to misfold and aggregate, first forming soluble oligomers, then insoluble paired helical filaments, and eventually the large, dense neurofibrillary tangles that clog nerve cells. These abnormal clumps disrupt normal cellular processes, impair synaptic function—the critical communication points between neurons—and ultimately lead to neuronal degeneration and the profound cognitive deficits observed in patients.
The new research specifically examined the protective role of SORLA, a protein that has previously garnered attention for its involvement in another key pathway implicated in Alzheimer’s disease. "In the last 15 or 20 years, considerable data has come out from our lab and other groups showing that SORLA can suppress one of the hallmarks of Alzheimer’s disease — amyloid-beta generation and accumulation," explained Timothy Huang, PhD, assistant professor in the Center for Neurologic Diseases at Sanford Burnham Prebys. This established role in amyloid-beta metabolism made SORLA a compelling candidate for investigation into tau pathology, as a protein capable of modulating both major pathological pathways could represent a powerful therapeutic target. "Very little was known, however, about whether SORLA affected the tau tangles reflected on the other side of the coin in Alzheimer’s disease," Dr. Huang added, underscoring the novel focus of their current study. SORLA is known to be a type I transmembrane receptor that functions as a sorting receptor, playing a crucial role in regulating protein trafficking within cells, particularly of proteins destined for degradation or secretion. Its ability to influence the processing of amyloid precursor protein (APP), thereby reducing amyloid-beta production, had already positioned it as a significant player in neurodegenerative research.
To investigate the potential protective effects of SORLA on tau pathology, the researchers embarked on a meticulously designed in vivo study. They crossbred two distinct mouse models: mice genetically engineered to produce elevated levels of human SORLA, and mice that inherently develop tau tangles, exhibit significant brain atrophy, and display measurable cognitive deficits, mirroring aspects of human tauopathies. This combined model allowed the team to directly study whether an increased abundance of SORLA could influence the intricate processes of tau accumulation and the subsequent cascade of damage that defines neurodegeneration. The tauopathy mouse model typically used in such studies often expresses mutant human tau, such as the P301L or P301S mutations, which are linked to familial forms of frontotemporal dementia and are known to spontaneously form neurofibrillary tangles and lead to neuronal loss. By introducing elevated SORLA into this disease context, the researchers could observe its impact on the initiation and progression of tau pathology.
The results from this innovative mouse model were remarkably promising, demonstrating that higher SORLA levels significantly interfered with several critical processes involved in tau tangle formation and neurodegeneration. Specifically, SORLA was found to reduce the excessive addition of phosphate groups to tau, a process known as hyperphosphorylation, which is the initial pathological step leading to tau detachment from microtubules and subsequent aggregation. This hyperphosphorylation is often driven by aberrant activity of kinases like GSK-3β and CDK5. By mitigating this initial step, SORLA effectively prevented tau from entering the pathological cascade. Furthermore, SORLA limited the ability of malformed tau proteins to act as "seeds" – a prion-like mechanism where misfolded tau propagates its pathological conformation to normal tau proteins, leading to the exponential growth of larger clumps and the spread of pathology across brain regions. Inhibiting this seeding process is considered a crucial strategy for halting disease progression.
Beyond these direct effects on tau pathology, the protective benefits of increased SORLA levels extended to broader indicators of neuronal health and function. Mice with more SORLA retained significantly healthier synapses, the vital communication points between neurons that are essential for learning and memory. The integrity of these synaptic structures is often severely compromised in tauopathies. Moreover, these mice showed better preservation of synaptic plasticity, which is the brain’s fundamental ability to strengthen or adjust those synaptic connections in response to experience – a process critical for memory formation and cognitive flexibility. The preservation of synaptic health and plasticity observed in the SORLA-overexpressing mice points to a functional rescue of brain circuits. "When you upregulate SORLA, you can suppress the negative effects found in tauopathies," stated Huijie Huang, PhD, a staff scientist in the Huang lab at Sanford Burnham Prebys and lead author of the study. She further added, "We found there was less brain atrophy and less tau accumulation, which was very exciting to see," highlighting the observable improvements at both the microscopic and macroscopic levels of brain structure and pathology.
To further solidify their findings and understand the physiological role of SORLA, the research team also investigated the consequences of SORLA deficiency. Some individuals carry mutations that disrupt Sorl1, the gene that provides instructions for making SORLA protein, suggesting a potential genetic link to increased disease risk. To compare the effects of excess SORLA with a complete absence of the protein, the researchers studied mice genetically modified to lack Sorl1. These animals experienced a starkly reverse outcome, providing compelling evidence for SORLA’s endogenous protective role. "The opposite turned out to be true when we deleted the ability to produce SORLA proteins," confirmed Tim Huang, senior and corresponding author of the manuscript. "A lack of SORLA exacerbated the harmful effects observed in tauopathies," he elaborated, indicating that without SORLA, the brain’s vulnerability to tau pathology significantly increases, leading to more aggressive disease progression. This dual experimental approach, observing both the benefits of increased SORLA and the detrimental effects of its absence, strongly supports SORLA as a critical protective factor against tau-mediated neurodegeneration.
To delve into the underlying mechanisms driving SORLA’s differential effects, the team employed a suite of advanced sequencing and mapping methods. These cutting-edge approaches allowed them to measure protein levels and gene activity with unprecedented precision in individual cells, while also providing spatial information on where RNA and proteins were located within the complex architecture of brain tissue. Techniques such as single-cell RNA sequencing, spatial transcriptomics, and proteomics were likely employed, offering a comprehensive view of the molecular landscape.
The sophisticated analysis revealed that increasing SORLA prevented detrimental changes in protein production at synapses, thereby preserving the delicate machinery required for neuronal communication. It also suppressed several other biological pathways known to be associated with the progression of tauopathy, suggesting a broad, pleiotropic protective action. A particularly compelling finding was SORLA’s influence on glial cells. Glial cells, including astrocytes and microglia, are crucial support cells in the brain, performing essential functions such as maintaining brain homeostasis, providing metabolic support to neurons, and mediating immune responses. However, in neurodegenerative diseases, these cells can become hyperactive and contribute to neuroinflammation, which is increasingly recognized as a major driver of neuronal damage and disease progression. Higher SORLA levels were found to reduce disease-related patterns of gene activity in these glial cells, suggesting that SORLA modulates the inflammatory response and helps maintain a healthier brain microenvironment.
"One particularly notable finding that we can build on is the upregulation of a member of the plexin-B family of receptors in the absence of SORLA," highlighted Huijie Huang. Plexins are a family of transmembrane receptors known for their roles in guiding axonal growth and neural circuit formation during development, but they also participate in immune responses and inflammation in the adult brain. The observation that these receptors were upregulated when SORLA was absent suggests a compensatory or pathological response. "There are unique drugs that can target this class of receptors that we may be able to apply to tau-related dementia disorders," added Tim Huang, pointing to an immediate and actionable therapeutic avenue. "One potential future direction is to repurpose these drugs to target overactivation of glial cells and perhaps reverse some of the phenotypes in tauopathies," he elaborated, emphasizing the exciting prospect of leveraging existing pharmaceuticals to tackle a novel target in the context of tauopathy. Repurposing drugs offers significant advantages, as these compounds often have established safety profiles and can potentially move through clinical trials more rapidly than entirely new drug candidates.
Looking ahead, the researchers are keen to examine more closely how individual types of brain cells—neurons, astrocytes, and microglia—respond when SORLA levels fluctuate. This cell-specific analysis is crucial because each cell type plays distinct roles in both health and disease, and understanding their individual responses to SORLA modulation will provide a more nuanced picture of its protective mechanisms. Their planned work includes grafting human neurons or glial cells into mouse brains, creating "humanized" models. This approach will allow them to study different SORLA mutations and their effects in a living disease environment that more closely mimics human pathology. "Mouse cells and human cells are different," explained Tim Huang. "Because we’re looking at human disease, it’s more informative if we can observe the modulation and dysfunction of SORLA in the context of a human cell inside of a diseased brain environment," he stressed, highlighting the importance of bridging the gap between animal models and human disease.
These future studies are expected to clarify precisely how SORLA protects the brain from toxic tau tangles at a molecular and cellular level and whether that protection can be therapeutically enhanced through pharmacological interventions. The work holds immense promise for identifying not only novel drug targets but also existing drugs that could be repurposed for the treatment of Alzheimer’s disease and other devastating dementias driven by tau pathology. The potential to strengthen the brain’s natural defenses against tau offers a powerful new strategy in the ongoing fight against these complex and debilitating neurodegenerative conditions.
Additional authors contributing to this impactful study include Christina Huan Shi, Wenqi Yang, Juan C. Piña-Crespo, Jay Bhatnagar, Julian Curatolo, Rabi Murad, Palak Shah, Alex Campos, Alexandra Houser, Rebecca A. Porritt, Giau Van Vo, Tongmei Zhang, Shengjie Feng and Kevin Y. Yip from Sanford Burnham Prebys, along with Qiang Xiao from The Scripps Research Institute. The critical research was generously supported by grants from the National Institutes of Health, including the National Cancer Institute and the National Institute on Aging, underscoring the broad significance and potential impact of these findings.
